Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of High-dose CKD-385 (Carvedilol) in Healthy Volunteers
NCT04083846Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carvedilol in hypertension (HTN), heart failure (HF) and angina pectoris (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve last at 48 hours and Maximum Plasma Concentration at 48 hours. Started Sep 2019; status: completed.
02
Drugs
carvedilol
03
Conditions
hypertension (HTN)heart failure (HF)angina pectoris
Beyond the preview
Go deeper on NCT04083846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083846.